Barely Significant
← all excerpts

Adverse events for biologics in patients with CRSwNP: A meta-analysis.

Clin Transl Allergy · 2022 · PMC9198683 · PMID 35734272

Europe PMCDOI
1
hedged sentence
0.7900
closest p · 15.8× alpha
0.7900
boldest claim

The sentences

failed to reach statistical significanceP = 0.79not close (p > 0.1)
In the subgroup analysis, both patients who were treated with dupilumab or omalizumab were significantly less likely to experience asthma exacerbation than those treated with placebo]RR 0.27, 95% CI 0.13–0.57; OR 0.31, 95% CI 0.12–0.78, Figure 1B ]; whereas the decreased incidence in patients who received mepolizumab failed to reach statistical significance ( P = 0.79) (RR 0.82, 95% CI 0.18–3.66).

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.